


# What's wrong with medical education?



Many medical graduates are unprepared for the realities of being a doctor. After five years of absorbing factual information, their creative thinking and problem solving skills are poor. Something is wrong with the way students are being taught.

In *Medical Education* Stella Lowry has put together the current views from the

profession, the GMC's recent review, and a national consensus inquiry by the King's fund. She examines issues such as:

- Selecting and assessing students
- Changing curricula
- Improving the quality of teaching
- Reorganising the preregistration year

The arguments and proposals for improvement are explained clearly, enabling all those involved in teaching medicine - virtually all doctors - to contribute to the debates. The book also provides a valuable insight, for teachers and students alike, into the way forward for medical education.

ISBN 0 7279 0789 1 112 pages 1993 UK £6.95, Overseas £8.00 (BMA Members £6.45, £7.50)

**BMJ**  
PUBLISHING GROUP

## ORDER FORM

Available from: British Medical Journal, P.O. Box 295, London WC1H 9TE, medical booksellers or the BMJ bookshop in BMA House

Please send me \_\_\_\_\_ copy/ies of **MEDICAL EDUCATION**

Membership No. \_\_\_\_\_

Name \_\_\_\_\_  
(Print Clearly)

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_  
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Address \_\_\_\_\_


Card No. \_\_\_\_\_ Exp \_\_\_\_\_

Postcode \_\_\_\_\_

Signature \_\_\_\_\_

Please send me a BMJ PUBLISHING GROUP CATALOGUE

# BASIC MOLECULAR AND CELL BIOLOGY



Second Edition 1993 UK £8.95; Overseas £11.00 (BMA Members £8.45; £10.50)

The study of disease at the molecular and cellular level is revolutionising medicine. Already spectacular progress has been made in identifying the genes involved in some diseases and in understanding cancer pathogenesis, opening up exciting new possibilities for treatment. In *Basic Molecular and Cell Biology* leaders in the field explain the techniques of molecular and cell biology, which are being applied in specialties as far apart as cardiology and diabetes, and describe their implications for medicine. It will enable doctors, students, and researchers to gain a basic understanding of the subject and some insight into the way in which the medical sciences will be moving over the next few years.

This second edition has been extensively updated and expanded, with four new chapters added.

#### CONTENTS INCLUDE:

- **Molecular and cell biology in clinical medicine: introduction**  
David Weatherall
- **The polymerase chain reaction: a tool for molecular medicine**  
A F Markham
- **Gene regulation**  
David S Latchman
- **Genes and cancer**  
Richard G Vile, Myra O McClure, Jonathan N Weber
- **An introduction to cells**  
Lewis Wolpert
- **The cell nucleus**  
R A Laskey
- **Sorting signals and cellular membranes**  
Graham Warren

**BMJ**  
PUBLISHING GROUP

#### ORDER FORM

Available from: **British Medical Journal, P.O. Box 295, London WC1H 9TE, medical booksellers or the BMJ bookshop in BMA House**

Please send me \_\_\_\_\_ copy/ies of **Basic Molecular and Cell Biology**    **Membership No.** \_\_\_\_\_

**Name** \_\_\_\_\_  
(Print Clearly)

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_  
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

**Address** \_\_\_\_\_

**Card No.** \_\_\_\_\_ **Exp** \_\_\_\_\_

**Signature** \_\_\_\_\_

\_\_\_\_\_ **Postcode** \_\_\_\_\_

Please send me a BMJ PUBLISHING GROUP CATALOGUE

# No. 1\*

Volume 5  
Number 2  
February 1991

## AIDS

<p><b>Editorial review</b></p> <p>125 HIV and harm reduction in injection drug users <i>R.P. Brecht</i></p> <p><b>Original papers</b></p> <p>137 Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes <i>B.A. Larder, P. Kellian and S.D. Kemp</i></p> <p>145 Inhibition of heterologous strains of HIV by antisense RNA <i>A. Rhodes and W. James</i></p> <p>153 HIV-1 indicator cell lines <i>A. Krüger, G.W.G. Wilkinson, S. Anglin and P.J. Greenaway</i></p> <p>159 Applications of a computer simulation model of the natural history of CD4 T-cell number in HIV-infected individuals <i>J.M.G. Taylor, S.J. Tan, B. Daniels and J.V. Giorgi</i></p> <p>169 Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees <i>M. Bello, M. Yagallo, M. Gianni, B. Gonzalez, A. D'Arduini, F. Baré-Sinoussi and J-C Ghackman</i></p> <p>177 Racial heterogeneity of HIV antigens in people with HIV infection <i>R.E. Chalker, E. Pacha, D.I. Swanson, T.C. Quinn, C. Herdickson, J.G. Bartlett and H. Paragadean</i></p> <p>181 The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users <i>S. Datta, W. Hall, N. Heather, J. Ward and A. World</i></p> <p>187 Needle-use practices among intravenous drug users in an area where needle purchase is legal <i>D.A. Calley, A.J. Saxon, G. Freeman and S. Whittaker</i></p> <p>195 Bacillus Calmette-Guérin immunisation in infants born to HIV-1-seropositive mothers <i>S. Lallemand-Le Coeur, M. Lallemand, D. Cheyrier, S. Ndiranguzi, J. Drucker and B. Larouze</i></p> <p>201 Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature <i>J. Añla, A. Salas, M. Riera, M. Udina, A. Galindo, J. Balanz, A. Balazterro, J. Buaño, F. Salvá and C. Villalonga</i></p>	<p><b>Short communications</b></p> <p>209 Negative correlation between blood cell counts and serum isopentenolone concentration in patients with HIV-1 infection <i>D. Pucha, G.M. Shearer, R.N. Bowtell, D.R. Lucey, M. Clerici, G. Reibnegger, E.R. Werner, R.A. Zajac and H. Wachter</i></p> <p>213 CD8+ T lymphocytes and progression to AIDS in HIV-infected men: some observations <i>R.E. Anderson, S.C. Shbooki, R. Royce, N.P. Jewell, W. Lang and W. Washienko Jr</i></p> <p>217 No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection <i>R.J.C. Gilson, A.E. Hawkins, G.K. Kelly, S.K. Gill and I.V.D. Weller</i></p> <p>221 Assessment of HIV status using the polymerase chain reaction in antibody-positive patients and high-risk antibody-negative haemophiliacs <i>G.I. Schoenberger, L. Barone, A. Wang-Simpson, B.H. Bornstein, B.H. Nightingale, W.J. Henley and P.A. Gatenby</i></p> <p><b>Editorial comment</b></p> <p>225 Antisense RNA to treat HIV infections <i>M.T. Boyd and T.F. Schultz</i></p> <p>227 Correspondence AIDS in the Americas details of the cost of zidovudine <i>A.M. Kimball et al.</i> Only temporary improvement in impaired neurological function in AIDS patients treated with zidovudine <i>I. Reinberg et al.</i> Exacerbation of HIV-associated myopathy by zidovudine <i>J.R. Berger et al.</i> Successful treatment of cryptococcal meningitis with liposomal amphotericin B <i>R.J. Collier et al.</i> Simple and inexpensive detection and confirmation of anti-HIV-1 in sera from Africa <i>S. Nick et al.</i> HIV infection in African patients with tropical pyomyiasis <i>I. Bélec et al.</i> Kaposi's disease in a patient infected with AIDS <i>S. Pasquazzi et al.</i> HIV-1 infection among prostitutes in Rio de Janeiro <i>Brazil C. De Meis et al.</i> Oral manifestations of HIV-1 infection in Zairean patients <i>Z. Mpendu et al.</i> Papanicolaou-associated oesophageal ulceration in a patient with AIDS <i>M. Schecher et al.</i></p> <p><b>Statistics - Meetings and errors</b></p>
--	---

\*Highest impact of all journals devoted specifically to AIDS according to the Institute of Scientific Information

ORDER FORM for AIDS, Vol 5, 1991

ISSN 0269-9370

Please send me the AIDS Volume 5, 1991 (twelve issues) at the following rate:

- Personal - from personal funds     £75/\$130\*
- Institutional     £150/\$255\*

Subscription rates include postage and packaging

**METHOD OF PAYMENT**

- Am Ex    VISA    MasterCard   Amount payable .....

Signature ..... Date .....

Card no [.....] Exp date [.....]

- Cheque/Eurocheque enclosed payable to Current Science Ltd
- Bank transfer (details available on request)

Prices in US\$ apply to subscribers in the USA & Canada ONLY  
Subscribers in Canada must add GST at the current rate  
& sterling must be drawn on a UK bank US\$ on a US bank

- Please invoice (institutional subscriptions ONLY)

**Guarantee** Your money will be refunded if you write cancelling your order within 30 days of receipt

Name

[.....]

Address

[.....]

Zip/Postcode

[.....]

Country

[.....]

EX

Return this form together with payment to:

**In USA & Canada:** CURRENT SCIENCE, Subscriptions, 20 North 3rd Street, Philadelphia, PA 19106-2113, USA or call TOLL FREE 1-800-552-5866 (in PA 215-574-2266)

**Outside USA & Canada:** CURRENT SCIENCE Ltd, Subscriptions, 34-42 Cleveland Street, London, W1P 5FB, UK

**In Japan contact:** Nankodo Co Ltd, 42-6 Hongo 3-chome, Bunkyo-ku, Tokyo 113, Japan

**In India contact:** Omega Scientific Publishers, 29 Sunder Nagar Market, New Delhi 110003, India


# Your resource...

*Sexually Transmitted Diseases* is your resource for the most current, comprehensive information available on all aspects of sexually transmitted disease. Its unique, multidisciplinary perspective provides insight into the latest advances in the field.

- **Diagnosis and Treatment**
- **Etiology ■ Pathology**
- **Epidemiology ■ Microbiology**
- **Public Health and Behavior**


Published bi-monthly, *Sexually Transmitted Diseases* brings you original articles on newly identified syndromes, new investigations into the mechanism of disease, descriptions of clinical experiences and reports on therapeutic trials. Features include notes from the CDC, NIH and ASHA, case reports and AVDA news.

*Subscribe to the resource you can rely on for the latest, most authoritative information on STDs!*



### **No-Risk Guarantee!**

If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.



☎ Call us today TOLL FREE  
 1-800-777-2295 (U.S. except AK)  
 or FAX your order 301-824-7390.  
 Published bi-monthly  
 Annual subscription rates:  
 Individual \$118.00 (U.S.) - \$130.00 (Other countries)  
 Institution \$165.00 (U.S.) - \$195.00 (Other countries)

Published by  
**J. B. Lippincott**

A **Wolters Kluwer** Company  
 Journals Division  
 J. B. Lippincott  
 227 East Washington Square  
 Philadelphia, PA 19106-3780  
 USA




# for the latest information on *Sexually Transmitted Diseases*

*Journal of the American Venereal Disease Association*  
**Julius Schachter, PhD, Editor**

**Abbreviated prescribing information for DIFLUCAN\* (fluconazole)** Presentation: Capsules containing 50mg, 150mg or 200mg fluconazole; intravenous infusion containing fluconazole 2mg/ml in 0.9% sodium chloride solution; Powder for Oral Suspension available as two dosage strengths containing either fluconazole 50mg/5ml or 200mg/5ml on reconstitution with 24ml water. *Indications and dosage:* Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Dermal fungal infections: 50mg once daily for up to 6 weeks (usually 2-4 weeks - see data sheet). Vaginal candidiasis: single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. *Administration:* DIFLUCAN may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. *Contra-indications:* Hypersensitivity to fluconazole or related azoles, pregnancy and women of childbearing potential unless adequate contraception is employed. *Warnings:* Lactation: Not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. *Drug interactions:* Anticoagulants, cyclosporin, oral sulphonylureas, phenytoin, rifampicin or theophylline. *Side-effects:* Nausea, abdominal discomfort, diarrhoea, flatulence and rarely anaphylaxis. *Legal Category:* POM. *Basic NHS Cost and Package Quantities:* DIFLUCAN capsules in calendar packs containing 7 x 50mg (£16.61, PL 57/0289), 7 x 200mg (£66.42, PL 57/0317) or 1 x 150mg (£7.12, PL 57/0290); Powder for Oral Suspension, 35ml bottle of 50mg/5ml (£16.61, PL 57/0343), 35ml bottle of 200mg/5ml (£66.42, PL 57/0344); Intravenous Infusion: 25ml (50mg) bottle (£7.32, PL 57/0315), 100ml (200mg) bottle (£29.28, PL 57/0315). Hospital prices are available on request. *References:* 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. et al. (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. et al. (1991), *Journal of Infection*, 23, 17-31. \*Trade Mark. Further information on request. **Pfizer Limited**, Sandwich, Kent.



AWARDED TO CENTRAL RESEARCH DIVISION OF PFIZER LIMITED



It takes a  
good antifungal  
routine  
to break the  
vicious cycle  
of Candida.

DIFLUCAN\* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.<sup>1</sup> It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.<sup>2,3</sup>

DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.<sup>4</sup> Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.<sup>5</sup>

**Diflucan**\* ORAL/I.V. Counters invasive fungal infection.  
fluconazole \*Trade Mark